{"transactions":[{"id":1440901,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T16:30:22.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":63905},"source":{"system":"sec-edgar","filing":"0000950170-24-090827","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090827/ownership.xml","form_type":"4"}},{"id":1440900,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:30:22.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":711827,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":711827},"source":{"system":"sec-edgar","filing":"0000950170-24-090827","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090827/ownership.xml","form_type":"4"}},{"id":1440899,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2024-08-05T16:30:22.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25042,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 379 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090827","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090827/ownership.xml","form_type":"4"}},{"id":1673143,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-23T17:45:02.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":63905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":63905,"derivative":{"underlying":"Common Stock","underlying_shares":63905},"source":{"system":"sec-edgar","filing":"0000950170-24-006692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024006692/ownership.xml","form_type":"4"}},{"id":1699560,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-27T16:15:11.000Z","date":"2023-12-22","kind":"exercise","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable."}],"balance_after":302242,"derivative":{"exercise_price":3.5,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000950170-23-073306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023073306/ownership.xml","form_type":"4"}},{"id":1699559,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2023-12-27T16:15:11.000Z","date":"2023-12-22","kind":"sale","planned":false,"acquired":false,"shares":8000,"price":41.451,"value":331608.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.45 to $41.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":24663,"source":{"system":"sec-edgar","filing":"0000950170-23-073306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023073306/ownership.xml","form_type":"4"}},{"id":1699558,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2023-12-27T16:15:11.000Z","date":"2023-12-22","kind":"exercise","planned":false,"acquired":true,"shares":8000,"price":3.5,"value":28000.0,"ownership":{"direct":true},"balance_after":32663,"source":{"system":"sec-edgar","filing":"0000950170-23-073306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023073306/ownership.xml","form_type":"4"}},{"id":1702297,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-21T20:24:07.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":13913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13913},"source":{"system":"sec-edgar","filing":"0000950170-23-072377","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072377/ownership.xml","form_type":"4"}},{"id":1702296,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2023-12-21T20:24:07.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":6256,"price":41.4232,"value":259143.5392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":24663,"source":{"system":"sec-edgar","filing":"0000950170-23-072377","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072377/ownership.xml","form_type":"4"}},{"id":1702295,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2023-12-21T20:24:07.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":13913,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,736 shares previously acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":30919,"source":{"system":"sec-edgar","filing":"0000950170-23-072377","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072377/ownership.xml","form_type":"4"}},{"id":2026657,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-08T20:25:02.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":13913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":13913,"derivative":{"underlying":"Common Stock","underlying_shares":13913},"source":{"system":"sec-edgar","filing":"0000899243-23-004355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004355/doc4.xml","form_type":"4"}},{"id":2026656,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-08T20:25:02.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":54749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":54749,"derivative":{"exercise_price":34.41,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":54749},"source":{"system":"sec-edgar","filing":"0000899243-23-004355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004355/doc4.xml","form_type":"4"}},{"id":2401913,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-11T18:42:58.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":75985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter."}],"balance_after":75985,"derivative":{"exercise_price":30.36,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":75985},"source":{"system":"sec-edgar","filing":"0000899243-22-005932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322005932/doc4.xml","form_type":"4"}},{"id":2876838,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T18:45:22.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":175438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":175438,"derivative":{"exercise_price":12.7,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":175438},"source":{"system":"sec-edgar","filing":"0000899243-21-005095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924321005095/doc4.xml","form_type":"4"}},{"id":4092268,"issuer":{"id":94539,"kind":"organization","name":"INVIVO THERAPEUTICS HOLDINGS CORP.","symbol":"NVIV"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-01-23T19:21:17.000Z","date":"2018-01-19","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.69,"expiration_date":"2028-01-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001179110-18-001034","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1292519/000117911018001034/edgar.xml","form_type":"4"}},{"id":4411677,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout.  One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date])."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2017-02-12","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411676,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."},{"field":"shares","element":"transactionShares","label":"F10","text":"This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout.  One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date])."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"}],"balance_after":1,"derivative":{"exercise_price":0,"expiration_date":"2017-02-12","underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411675,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":1174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."},{"field":"shares","element":"transactionShares","label":"F9","text":"This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2017-02-12","underlying":"Common Stock","underlying_shares":1174},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411674,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":1494,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."},{"field":"shares","element":"transactionShares","label":"F8","text":"This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"}],"balance_after":5392,"derivative":{"exercise_price":0,"expiration_date":"2019-02-22","underlying":"Common Stock","underlying_shares":1494},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411673,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."},{"field":"shares","element":"transactionShares","label":"F7","text":"This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017"}],"balance_after":1948,"derivative":{"exercise_price":0,"expiration_date":"2018-02-23","underlying":"Common Stock","underlying_shares":728},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411672,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"other","acquired":false,"shares":1216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":2676,"derivative":{"exercise_price":0,"expiration_date":"2018-02-23","underlying":"Common Stock","underlying_shares":1216},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411671,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"other","acquired":false,"shares":1198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":6886,"derivative":{"exercise_price":0,"expiration_date":"2019-02-22","underlying":"Common Stock","underlying_shares":1198},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411670,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"other","acquired":false,"shares":1378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":1174,"derivative":{"exercise_price":0,"expiration_date":"2017-02-12","underlying":"Common Stock","underlying_shares":1378},"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411669,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":1083,"price":274.76,"value":297565.08,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":7177,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411668,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":8260,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411667,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":553,"price":274.76,"value":151942.28,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":5960,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411666,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":1174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":6513,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411665,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":485,"price":287.63,"value":139500.55,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":5339,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411664,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":1494,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":5824,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411663,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":335,"price":284.75,"value":95391.25,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4411662,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Common Stock","published_at":"2017-03-02T22:12:03.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award.  Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017.  Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017."}],"balance_after":4665,"source":{"system":"sec-edgar","filing":"0001127602-17-009803","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217009803/form4.xml","form_type":"4"}},{"id":4440893,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"officer":true,"officer_title":"EVP Human Resources"}}],"security":"Restricted Stock Unit","published_at":"2017-02-18T01:17:59.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":6380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":6380,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":6380},"source":{"system":"sec-edgar","filing":"0001127602-17-007108","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217007108/form4.xml","form_type":"4"}},{"id":4484030,"issuer":{"id":94539,"kind":"organization","name":"INVIVO THERAPEUTICS HOLDINGS CORP.","symbol":"NVIV"},"owners":[{"id":88500,"kind":"person","name":"DiPietro Kenneth","position":1,"cik":"0001540188","reported_name":"DiPietro Kenneth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-23T16:00:36.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":4.35,"expiration_date":"2027-01-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001179110-17-001169","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1292519/000117911017001169/edgar.xml","form_type":"4"}}]}